Analysed ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) News Sources
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
11-06-2026
yahoo.com
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
12-06-2026
yahoo.com
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
21-07-2026
yahoo.com
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
28-07-2026
yahoo.com
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
07-08-2026
yahoo.com
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
24-09-2026
yahoo.com
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
29-09-2026
yahoo.com
What is the current price of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)?
The current price of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) is $2.91.
ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) since the previous trading day is $0.26.
ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) since the previous trading day is 9.8113%.
What is the most recent average sentiment score for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)?
The most recent average sentiment score for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)?
The most recent sentiment for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) is .
SEC-8K** Filing Available For ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.